Details

Autor(en) / Beteiligte

• Craig, Robert A.
• Fox, Brian M.
• Hu, Cheng
• Lexa, Katrina W.
• Osipov, Maksim
• Thottumkara, Arun P.
• Larhammar, Martin
• Miyamoto, Takashi
• Rana, Anil
• Kane, Lesley A.
• Yulyaningsih, Ernie
• Solanoy, Hilda
• Nguyen, Hoang
• Chau, Roni
• Earr, Timothy
• Kajiwara, Yuji
• Fleck, Daniel
• Lucas, Anthony
• Haddick, Patrick C. G.
• Takahashi, Ryan H.
• Tong, Vincent
• Wang, Jing
• Canet, Mark J.
• Poda, Suresh B.
• Scearce-Levie, Kimberly
• Srivastava, Ankita
• Sweeney, Zachary K.
• Xu, Musheng
• Zhang, Rui
• He, Jianrong
• Lei, Yanan
• Zhuo, Zheng
• de Vicente, Javier

Titel

Discovery of Potent and Selective Dual Leucine Zipper Kinase/Leucine Zipper-Bearing Kinase Inhibitors with Neuroprotective Properties in In Vitro and In Vivo Models of Amyotrophic Lateral Sclerosis

Ist Teil von

• Journal of medicinal chemistry, 2022-12, Vol.65 (24), p.16290-16312

Ort / Verlag

United States: American Chemical Society

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Dual leucine zipper kinase (DLK) and leucine zipper-bearing kinase (LZK) are regulators of neuronal degeneration and axon growth. Therefore, there is a considerable interest in developing DLK/LZK inhibitors for neurodegenerative diseases. Herein, we use ligand- and structure-based drug design approaches for identifying novel amino-pyrazine inhibitors of DLK/LZK. DN-1289 (14), a potent and selective dual DLK/LZK inhibitor, demonstrated excellent in vivo plasma half-life across species and is anticipated to freely penetrate the central nervous system with no brain impairment based on in vivo rodent pharmacokinetic studies and human in vitro transporter data. Proximal target engagement and disease relevant pathway biomarkers were also favorably regulated in an in vivo model of amyotrophic lateral sclerosis.